VSVorapun Senanarong

Vorapun Senanarong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vorapun Senanarong has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Chatchawan Rattanabannakit

    Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    8 shared publications
  • Natthamon Wongkom

    Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Bangkok, Thailand

    6 shared publications
  • Pathitta Dujada

    Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    6 shared publications
  • Atthapon Raksthaput

    Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    5 shared publications
  • Chatchawan Rattanabannakit

    Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    5 shared publications
  • Sunisa Chaichanettee

    Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    5 shared publications

Latest Publications

  • Open Access

    Cost-utility analysis of cerebrospinal fluid versus blood biomarkers for early detection of Alzheimer’s disease and mild cognitive impairment in Thailand: a modeling study

    by Pattara Leelahavarong, Juthamas Prawjaeng, Pakkanan Angkab, Natthamon Wongkom, Philip Scheltens, Varalak Srinonprasert, Vorapun Senanarong

    To evaluate the cost-utility of cerebrospinal fluid (CSF) and blood-based amyloid beta biomarkers for early detection of Alzheimer’s disease and mild


  • Open Access

    Validation of blood biomarkers for Alzheimer Disease in Thai Cohort

    by Vorapun Senanarong, Tanyaluck Thientunyakit, Chatchawan Rattanabannakit, Natthamon Wongkom, Pathitta Dujada, Atthapon Raksthaput, Sunisa Chaichanettee, Paphawadee Phoyoo, Lertchai Wachirutmangur, Philip Scheltens

    Background: Our objective of this study is to identify suitable local cut‐off values of plasma‐based biomarkers in Alzheimer disease (AD) in the discrimination of AD and non‐AD subgroups in Thai population. Method: We conducted a prospective study in 51 individuals with clinically diagnosed AD (15 had amyloid PET positive (≥ 30 centiloid, CL), 16 had CSF Aβ 42 ≤547 pg/mL and CSF pTau 181 >57 pg/mL regarded as amyloid positive AD), 34 individuals with clinically diagnosed non‐AD dementia (9 had amyloid PET negative, 25 had CSF Aβ 42 and CSF pTau181 negative), and 12 individuals with mild cognitive impairment (MCI) or normal controls (6 had amyloid PET negative and 6 had CSF Aβ 42 and CSF pTau181 negative). Aβ‐PET using 18F‐florbetapir and plasma biomarkers (Aβ 40 , Aβ 42 , p ‐tau181, pTau 217, Glial fibrillary acidic protein (GFAP)) were obtained in all subjects within 6 months before or after the PET study. The quantitative analysis of Aβ‐PET to obtain Centiloid (CL) followed the standard method using the SPM8 pipeline. Blood biomarker analysis utilized Simoa® Quanterix immunoassay. CSF Aβ42, t‐Tau and p ‐Tau were measured separately, in duplicate, by commercially available sandwich ELISA kits (Innotest; Innogenetics/Fujirebio, Ghent, Belgium). Participants underwent a standardized diagnostic dementia evaluation. Result: Among 97 individuals, 54 (55.7%) amyloid positive and 43(44.3%) amyloid negative individuals were included in this blood biomarkers validation study. Mean age was 65.86(8.01) years, mean TMSE was 19.57(7.44) and mean MOCA was 15.48(7.27). Mean(SD) plasma Aβ 42/40, pTau181, pTau 217, NFL, and GFAP were 0.054(0.013) pg/mL, 37.591(18.975) pg/mL, 1.088(0.949) pg/mL, 102.703(412.308) pg/mL, and 162.459(107.223) pg/mL respectively. Utilizing single cut off from ROC analysis: the cut off points are as followed; for plasma Aβ42/40≤0.054pg/mL (AUC(SE)=0.716(0.064), p 32.7pg/mL (AUC(SE)=0.812(0.058), p 0.522pg/mL (AUC(SE)=0.856(0.056), p 119pg/mL (AUC(SE)=0.796(0.058), p p ‐tau217 was best differentiates AD positive from AD negative groups, followed by plasma GFAP, pTau181, and Aβ42/40 ratio. Thank you Health Systems Research Institute (Thailand) grant support for this study


  • Open Access

    Early Onset Dementia: Experience from Thailand

    by Vorapun Senanarong, Chatchawan Rattanabannakit, Natthamon Wongkom, Pathitta Dujada, Atthapon Raksthaput, Sunisa Chaichanettee, Theeraphong ‐ Pho‐Iam, Chanin Limwongse, Philip Scheltens, Pedro Rosa‐Neto, et al.

    Background: Early‐onset dementia (EOD) is a uncommon form of dementia that afflicts people before age 65. Only a few studies analyzing the genetics of EOD have been performed in Thai population. EOD remains a challenge due to the diverse genetic and clinical heterogeneity of these diseases. The aim of this study was to investigate the genetic spectrum of Thai EOD and those with familial history of dementia. Method: 150 subjects with EOD AND 18 individuals with familial dementia were recruited. Targeted next generation (NGS) analyses were performed to screen 38 genes associated with dementia. Result: Subject characteristics were demonstrated in table 1. Fifteen had pathogenic variants. Among pathogenic (47%) and likely pathogenic (53%) variants, 5 (33.33%) were in PSEN1 (c.417G>T, p.Met139Ile), (c.344A>G, p.Tyr115Cys), (c.817G>A, p.Glu273Lys), (c.817G>A, p.Glu273Lys), (c.485T>C, p.Ile162Thr)); 2 (13.33%) in CSF1R (c.704T>G, p.Val235Gly), (c.2522A>G, p.Tyr841Cys); 1(6.67%) each in ABCA7 (c.5571‐1G>C, p.?), SNCB (c.372G>A, p.Gln124=), SORL1 (c.2212G>A, p.Gly738Arg), APP (c.2149G>A, p.Val717Ile), VAPB (c.301G>T, p.Asp101Tyr), GRN (c.276C>A, p.Cys92Ter), SOD1 (c.143T>C, p.Val48Ala), and NOTCH3 (c.1630C>T, p.Arg544Cys). Among these, the PSEN1 variant c.817G>A (p.Glu273Lys) had not previously been reported. 61 had variants of uncertain significance (VUS). Graphs 1‐3 showed results of NGS for dementia in the whole cohort, in those with pathogenic variants, and in those with VUS. Conclusion: Our study demonstrated the genetic spectrum of EOD and familial dementia in Thai patients. The utilization of next‐generation sequencing could help deciphering the genetic causes of Alzheimer's disease. The genetic testing of known causal genes in EOD patients can help make a precise diagnosis. We acknowledged Thailand Science Research and Innovation for supporting this study.

  • EEGMeNet: End-to-End Multitask Neural Network for Brain-Based Mental Workload Classification

    by Supavit Kongwudhikunakorn, Wuttikorn Ponwitayarat, Suktipol Kiatthaveephong, Wipamas Polpakdee, Tohru Yagi, Vorapun Senanarong, Piyalitt Ittichaiwong, Theerawit Wilaiprasitporn

    High mental workload poses significant challenges across various domains, often impairing performance and decision-making. Recent advancements in Internet of Things (IoT) technologies have enabled continuous monitoring of brain activity via electroencephalography (EEG), facilitating real-time assessment of mental workload during task execution. Early detection of elevated workload levels is essential for mitigating potential adverse outcomes. This paper presents EEGMeNet, an end-to-end, multi-task neural network designed to classify mental workload levels from EEG signals. EEGMeNet consists of four key components: (1) a local feature learner that extracts spectral and spatial characteristics, (2) a global feature learner employing attention-based mechanisms to model temporal dependencies, (3) a feature preserver that enhances representation learning, and (4) a supervised classifier for mental workload classification. The proposed model is evaluated across five mental task EEG datasets—including one acquired in clinical settings—under both within-subject and cross-subject, as well as within-session and cross-session classification paradigms. EEGMeNet outperforms nine state-of-the-art baselines, achieving an accuracy of 87.49±2.66% and an F1 score of 85.26±2.63% in cross-subject evaluations, showing at least a 9% improvement in accuracy and a 12% gain in F1 score. Moreover, EEGMeNet demonstrates low prediction time complexity, making it well-suited for deployment on resource-constrained IoT devices. These results underscore EEGMeNet’s robustness to inter-subject and multi-session EEG variability, validating its effectiveness for real-world EEG-IoT applications. This work establishes EEGMeNet as a promising foundation for future mental workload classification research in EEG-IoT environments.


  • Open Access

    A Comparison of the Brain Parameters of Thais with Normal Cognition, Mild Cognitive Impairment, and Dementia

    by Pariwat Wisetwongsa, Sitha Piyaselakul, Yudthaphon Vichianin, Pipat Chiewvit, Chatchawan Rattanabannakit, Saowalak Hunnangkul, Natthamon Wongkom, Pathitta Dujada, Vorapun Senanarong

    Objectives: This study examined the differences in brain volume and cortical thickness among individuals with normal cognition (NC) and those with NCDs, including mild cognitive impairment (MCI) and dementia. The aim was to identify the brain parameters supporting clinical decision-making for NCDs. Method: A total of 116 participants were categorized into dementia, MCI, and NC groups, and their brain scans using structural magnetic resonance imaging (MRI) were processed and automatedly analyzed with FreeSurfer to obtain the absolute brain volume, volume normalized by intracranial volume (ICV), and cortical thickness. Patients with dementia exhibited a significantly smaller brain volume and cortical thickness than the MCI and NC groups. Results: The left amygdala/ICV ratio demonstrated excellent performance in diagnosing early NCDs, with a cutpoint of ≤0.089, providing 83.30% sensitivity, 84.20% specificity, and 83.82% accuracy. For MCI, a cutpoint of ≤0.099 for the left amygdala/ICV yielded 96.70% sensitivity, 83.30% specificity, and 88.46% accuracy. Conclusions: The findings suggested that reductions in brain volume and cortical thickness correlate with cognitive decline. Utilizing FreeSurfer and MRI data, particularly the left amygdala/ICV ratio, may serve as a valuable biomarker for the early identification of individuals at risk for developing NCDs.

  • Open Access

    The Utility of CSF Biomarkers in Diagnosing Alzheimer’s Disease: A Thai Cohort Study

    by Witsarut Nanthasi, Chatchawan Rattanabannakit, Natthamon Wongkom, Pathitta Dujada, Atthapon Raksthaput, Sunisa Chaichanettee, Paphawadee Phoyoo, Leatchai Wachirutmanggur, Seong Soo A. An, Vorapun Senanarong

    Introduction: Cutoff values for cerebrospinal fluid biomarkers vary by analytic technique and population, which complicates the differentiation of Alzheimer’s disease (AD) from non-AD dementias. We aimed to establish local cerebrospinal fluid biomarker cutoffs within a Thai cohort. Materials and Methods: We recruited 68 patients with various forms of dementia from the Memory Clinic at Siriraj Hospital, Thailand. Each patient underwent clinical subtyping for dementia, and their cerebrospinal fluid levels of Aβ42, p-tau181, and t-tau were quantified using the Fujirebio INNOTEST ELISA. We then employed a data-driven approach, specifically a Z-score-based Gaussian Mixture Model, to define intersection cutoffs for Aβ42, p-tau181, t-tau, and the p-tau181/Aβ42 ratio. These established biomarker cutoffs were subsequently incorporated with clinical manifestations to refine the clinicobiological diagnoses. Results: Our study included 67 patients (mean age 65.5 ± 7.4 years, 61.2% female). Using a data-driven approach, we established the following CSF biomarker cutoffs for identifying AD in this Thai cohort: Aβ42 at 492.67 pg/mL, p-tau181 at 44.00 pg/mL, t-tau at 545.97 pg/mL, and the p-tau181/Aβ42 ratio at 0.057. After incorporating these CSF biomarker results with clinical profiles, the diagnoses changed in 17.9% of the patients. Conclusions: In this study, CSF cutoffs for differentiating AD from non-AD dementia were established through a data-driven approach, which has been demonstrated as a valid alternative methodology. The integration of clinical and biological profiles is paramount in achieving accurate dementia diagnoses.


  • Open Access

    Correlation between blood biomarkers and neuropsychiatric symptoms: Siriraj cohort, Thailand

    by Vorapun Senanarong, Chatchawan Rattanabannakit, Witsarut Nanthasi, Natthamon Wongkom, Pathitta Dujada, Paphawadee Phoyoo, Lertchai Wachirutmangur

    Background: We explored the relationship of neuropsychiatric symptoms (assesses by NPI) and Alzheimer disease pathophysiology from blood AB42/40, GFAB, NFL, and pTau181. We also investigated if age and cognition were related to these neuropsychiatric symptoms.Method: 222 subjects included 96 dementia, 66 MCI, and 60 normal controls (NC). Spearman correlation was used to calculation the correlation coefficient. Mann‐Whitney U test is used to compare biomarkers of those with and without subitem symptoms of NPI.Result: Mean ages were 71.26±9.82 years old in dementia group, 68.83±8.01 years old in MCI group, and 59.28±9.22 years old in NC group. Sum of 12 NPI subscale scores showed significant low correlation (r=0.20‐0.29) were correlated with blood AB42/AB40, Ptau 181, NFL, and GFAB. Sum of 12 NPI subscale scores showed significant moderate correlation with age and global cognition (assessed by Thai mental state examination, TMSE). Blood pTau181 displayed low correlation with hallucination, depression, anxiety, apathy, and irritability subscale scores. There was a significant low correlation between blood AB42/AB40 and delusion and irritability subscale scores. Blood NFL showed low correlation with euphoria, a, apathy, disinhibition, irritability, and aberrant motor activity. Inflammation process appeared to be significantly related with psychosis, apathy, disinhibition, and irritability. After controlled by age and TMSE; only apathy and AMA NPI subscale scores were correlated to NFL and GFAB accordingly.Conclusion: We discovered that psychosis and mood factors of NP symptoms were related to blood pTau. While most frontal factors of NP symptoms showed significant relationship with axonal destruction and microglia activation/inflammation.This study was supported by grants from Health Systems Research Institute (HSRI), Thailand.


  • Open Access

    Validation of the Adapted Picture Version of the Pyramids and Palm Trees Test for Thais with Dementia

    by Duangkamol Singwicha, Chatchawan Rattanabannakit, Saowalak Hunnangkul, Atthapon Raksthaput, Sunisa Chaichanettee, Natthamon Wongkom, Pathitta Dujada, Vorapun Senanarong

    Objective: We aimed to validate Pyramids and Palm Trees test (PPT) in dementia cohort and explore reliability measurement of this test. Materials and Methods: The study was designed as a cross-sectional study. A total of 30 subjects were recruited from the Memory Clinic at Siriraj Hospital, Thailand: 15 non-dementia adults and 15 dementia patients (mild to moderate stage). In content validation, the picture version of the PPT was given to experts to evaluate the content of the test. According to consensus, some pictures with cultural issues were adapted to be more culturally appropriate. For concurrent validation, the PPT was compared against standard tests (Thai Mental Status Examination (TMSE), Boston Naming Test (BNT), Animal Fluency Test) using Spearman correlation and Receiver Operating Characteristic (ROC) analysis. The internal reliability of the PPT was assessed using Intraclass Correlation Coefficient (ICC) and Cronbach’s Alpha. Results: Among the 52 pictures in the PPT, 25 pictures were changed. The median score of the PPT was 49 for non-dementia group and 43 for dementia group. The PPT was significantly correlated with the Animal Fluency Test, the BNT, and the TMSE. ROC analysis revealed an Area Under the Curve (AUC) of 0.8. ICC was 0.86 (95% CI, 0.78 to 0.92), and internal consistency was 0.87, indicating good to satisfactory reliability. Conclusions: The PPT demonstrated good concurrent validity compared to the TMSE, BNT, and Animal Fluency Test in dementia patients. Based on this study, it is recommended as a test for semantic memory in Thai individuals with dementia.


  • Open Access

    Characteristics of Creutzfeldt-Jakob disease at Siriraj Hospital, Thailand: Case series and literature review

    by Chaisak Dumrikarnlert, Nuttapong Kanokkawinwong, Chatchawan Rattanabannakit, Vorapun Senanarong


  • Open Access

    Feature-Based Classification of Mild Cognitive Impairment and Alzheimer’s Disease Based on Optical Coherence Tomographic Angiographic Image

    by Sarinporn Visitsattapongse, Areerat Maneerat, Adisak Trinavarat, Chatchawan Rattanabannakit, Ekkaphop Morkphrom, Vorapun Senanarong, Varalak Srinonprasert, Dittapong Songsaeng, La-Ongsri Atchaneeyasakul, Chuchart Pintavirooj

    Alzheimer’s disease is a type of neurodegenerative disorder that is characterized by the progressive degeneration of brain cells, leading to cognitive decline and memory loss. It is the most common cause of dementia and affects millions of people worldwide. While there is currently no cure for Alzheimer’s disease, early detection and treatment can help to slow the progression of symptoms and improve quality of life. This research presents a diagnostic tool for classifying mild cognitive impairment and Alzheimer’s diseases using feature-based machine learning applied to optical coherence tomographic angiography images (OCT-A). Several features are extracted from the OCT-A image, including vessel density in five sectors, the area of the foveal avascular zone, retinal thickness, and novel features based on the histogram of the range-filtered OCT-A image. To ensure effectiveness for a diverse population, a large local database for our study was collected. The promising results of our study, with the best accuracy of 92.17,% will provide an efficient diagnostic tool for early detection of Alzheimer’s disease.